Common variations in the genes encoding C-reactive protein, tumor necrosis factor-α, and interleukin-6, and the risk of clinical diabetes in the women's health initiative observational study

Clinical Chemistry

Volumn 57, Issue 2, 2011, Pages 317-325

  Chan, Kei Hang K ^a   Brennan, Kathleen ^a,b   You, Nai Chieh Y ^a   Lu, Xuyang ^a   Song, Yiqing ^c   Hsu, Yi Hsiang ^d,e   Chaudhuri, Gautum ^a,b   Nathan, Lauren ^a,b   Tinker, Lesley ^f   Liu, Simin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POSTMENOPAUSE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; HUMANS; INTERLEUKIN-6; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551469885     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.154526     Document Type: Article

References (38)

1. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-8.
2. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2003;52:1799-805.
3. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-21.
4. McMillan DE. Increased levels of acute-phase serum proteins in diabetes. Metabolism 1989;38: 1042-6.
5. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-600.
6. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004;53:693-700. (Pubitemid 38270639)
7. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77.
8. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 2003;26: 2754-7.
9. Hu G, Jousilahti P, Tuomilehto J, Antikainen R, Sundvall J, Salomaa V. Association of serum C-reactive protein level with sex-specific type 2 diabetes risk: a prospective Finnish study. J Clin Endocrinol Metab 2009;94:2099-105.
10. Onat A, Can G, Hergenc G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabolism 2008;57:207-14.
11. Liu S, Tinker L, Song Y, Rifai N, Bonds DE, Cook NR, et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med 2007;167:1676-85.
12. Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007;56:872-8.
13. Lee CC, You NC, Song Y, Hsu YH, Manson J, Nathan L, et al. Relation of genetic variation in the gene coding for C-reactive protein with its plasma protein concentrations: findings from the Women's Health Initiative Observational Cohort. Clin Chem 2009;55:351-60.
14. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 2005;178: 139-45.
15. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Tataranni PA, Bogardus C, Hanson RL. A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 2003;78:136-44.
16. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
17. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003;13:S5-17.
18. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7: 231-40.
19. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
20. Hao K, Liu S, Niu T. A sparse marker extension tree algorithm for selecting the best set of haplotype tagging single nucleotide polymorphisms. Genet Epidemiol 2005;29:336-52.
21. Hsu YH, Niu T, Song Y, Tinker L, Kuller LH, Liu S. Genetic variants in the UCP2-UCP3 gene cluster and risk of diabetes in the Women's Health Initiative Observational Study. Diabetes 2008;57: 1101-7.
22. Song Y, You NC, Hsu YH, Sul J, Wang L, Tinker L, et al. Common genetic variation in calpain-10 gene (CAPN10) and diabetes risk in a multiethnic cohort of American postmenopausal women. Hum Mol Genet 2007;16:2960-71.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodol) 1995;57:289-300.
24. Spinarova L, Spinar J, Vasku A, Pavkova-Goldbergova M, Ludka O, Tomandl J, Vitovec J. Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients. Exp Mol Pathol 2008;84: 251-5.
25. Shiau MY, Wu CY, Huang CN, Hu SW, Lin SJ, Chang YH. TNF-α polymorphisms and type 2 diabetes mellitus in Taiwanese patients. Tissue Antigens 2003;61:393-7.
26. Zeggini E, Groves CJ, Parkinson JR, Halford S, Owen KR, Frayling TM, et al. Large-scale studies of the association between variation at the TNF/LTA locus and susceptibility to type 2 diabetes. Diabetologia 2005;48:2013-7.
27. Koch M, Rett K, Volk A, Maerker E, Haist K, Weisser M, et al. The tumour necrosis factor α -238 G → A and -308 G → A promoter polymorphisms are not associated with insulin sensitivity and insulin secretion in young healthy relatives of type II diabetic patients. Diabetologia 2000;43:181-4.
28. Rasmussen SK, Urhammer SA, Jensen JN, Hansen T, Borch-Johnsen K, Pedersen O. The -238 and -308 G→A polymorphisms of the tumor necrosis factor α gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. J Clin Endocrinol Metab 2000;85:1731-4.
29. Araujo F, Pereira AC, Mota GF, Latorre Mdo R, Krieger JE, Mansur AJ. The influence of tumor necrosis factor -308 and C-reactive protein G1059C gene variants on serum concentration of C-reactive protein: evidence for an age-dependent association. Clin Chim Acta 2004;349: 129-34.
30. Sookoian SC, González C, Pirola CJ. Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes Res 2005;13: 2122-31.
31. Ranjith N, Pegoraro RJ, Naidoo DP, Shanmugam R, Rom L. Genetic variants associated with insulin resistance and metabolic syndrome in young Asian Indians with myocardial infarction. Metab Syndr Relat Disord 2008;6:209-14.
32. Koh SJ, Jang Y, Hyun YJ, Park JY, Song YD, Shin KK, et al. Interleukin-6 (IL-6) -572C→G promoter polymorphism is associated with type 2 diabetes risk in Koreans. Clin Endocrinol (Oxf) 2009;70:238-44.
33. Herbert A, Liu C, Karamohamed S, Schiller J, Liu J, Yang Q, et al. The -174 IL-6 GG genotype is associated with a reduced risk of type 2 diabetes mellitus in a family sample from the National Heart, Lung and Blood Institute's Framingham Heart Study. Diabetologia 2005;48:1492-5.
34. Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK, et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 2006;55:2915-21.
35. Illig T, Bongardt F, Schopfer-Wendels A, Huth C, Heid I, Rathmann W, et al. Genetics of type 2 diabetes: impact of interleukin-6 gene variants. Gesundheitswesen 2005;67(Suppl 1):S122-6.
36. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB. Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 2006;15:1914-20.
37. Vozarova B, Fernandez-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, et al. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 2003;112:409-13.
38. Zee RY, Germer S, Thomas A, Raji A, Rhees B, Ridker PM, et al. C-reactive protein gene variation and type 2 diabetes mellitus: a case-control study. Atherosclerosis 2008;197:931-6.